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Abstract
Background: Preterm labour is the main cause of perinatal morbidity and mortality in the
Western world. At present, there is evidence that tocolysis for 48 hours is useful in women with
threatened preterm labour at least before 32 weeks. This allows transfer of the patient to a
perinatal centre, and maximizes the effect of corticosteroids for improved neonatal survival. It is
questionable whether treatment with tocolytics should be maintained after 48 hours.
Methods/Design: The APOSTEL II trial is a multicentre placebo-controlled study. Pregnant
women admitted for threatened preterm labour who have been treated with 48 hours
corticosteroids and tocolysis will be eligible to participate in the trial between 26+0 and 32+2 weeks
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BMC Pregnancy and Childbirth 2009, 9:42 http://www.biomedcentral.com/1471-2393/9/42gestational age. They will be randomly allocated to nifedipine (intervention) or placebo (control)
for twelve days or until delivery, whatever comes first.
Primary outcome is a composite of perinatal death, and severe neonatal morbidity up to evaluation
at 6 months after birth. Secondary outcomes are gestational age at delivery, number of days in
neonatal intensive care and total days of the first 6 months out of hospital. In addition a cost-
effectiveness analysis will be performed. Analysis will be by intention to treat. The power
calculation is based on an expected 11% difference in adverse neonatal outcome. This implies that
406 women have to be randomised (two sided test, β 0.2 at alpha 0.05).
Discussion: This trial will provide evidence as to whether maintenance tocolysis reduces severe
perinatal morbidity and mortality in women with threatened preterm labour before 32 weeks.
Trial Registration: Clinical trial registration: http://www.trialregister.nl, NTR 1336, date of
registration: June 3rd 2008.
Background
Preterm birth is the most common cause of neonatal mor-
bidity and death worldwide [1]. Two thirds of the preterm
births occur as a result of spontaneous labour beginning
with spontaneous contractions or with preterm rupture of
membranes. Preterm birth accounts for approximately
75% of all neonatal deaths and 50% of childhood neuro-
logical morbidities [2]. Moreover, it is associated with
high immediate and long-term costs after discharge from
the hospital [3]. These include costs for special education
services and institutionalised care for physically and men-
tally disabled infants [4]. The prevalence of adverse neo-
natal outcome is strongly related to gestational age at
delivery and declines from 77% at 24-27 weeks to less
then 2% at 34 weeks and beyond [5]. Perinatal death and
morbidity are not only strongly related to early gestational
age but also to whether or not antenatal corticosteroids
are administered [6] and whether a preterm infant is
transferred to a tertiary care centre before or after birth.
Postponing delivery for 48 hours with tocolytics in order
to allow maximal effect of maternal parenteral steroid
administration and transfer of the mother to a centre with
Neonatal Intensive Care Unit (NICU) facilities is therefore
standard treatment in women with the diagnosis of
threatened preterm labour before 32 weeks gestational
age [7].
Approximately 75% of women with a diagnosis of threat-
ened preterm labour have not delivered after the first 48
hours of tocolytic therapy with nifedipine. After this 48
hour period the risk of preterm delivery persists. Two
weeks after treatment for threatened preterm labour with
nifedipine 65% of women are still pregnant [8].
Fetal fibronectin can be helpful in selecting women at risk
for preterm delivery. Management based on knowledge of
fetal fibronectin results significantly reduces preterm
delivery less than 37 weeks compared to management
without knowledge of these results (RR 0.54, 95% confi-
dence interval 0.34 to 0.87). However the incidence of
preterm delivery less than 34, 32 and 28 weeks were sim-
ilar in both groups [9].
In national and international guidelines, a uniform treat-
ment of threatened preterm delivery after 48 hours of toc-
olytic therapy has not yet been developed. Some
obstetricians maintain tocolytic therapy until term, 37
weeks gestational age, whereas others stop tocolytics after
48 hours irrespective of gestational age or continue until
for example 28 weeks gestational age. Maintenance treat-
ment with several tocolytic agents has been being carried
out in daily practice and include betamimetics [10,11],
magnesium sulphate, indomethacin and calcium channel
blockers [12] in order to achieve further prolongation of
pregnancy and improvement of neonatal outcome. At
present, no beneficial effect on perinatal outcome of such
prolonged treatment has been established [13]. On one
hand, tocolytic maintenance therapy with calcium chan-
nel blockers might be beneficial due to a positive effect on
gestational age and possibly on neonatal outcome. On the
other hand, use of tocolytics is associated with rare but
severe side effects on mother and child [14,15], and may
increase the risk of some perinatal complications - includ-
ing intra-uterine infection.
Two systematic reviews included in DARE [16,17] and the
Cochrane systematic review on maintenance tocolysis
with nifedipine [12] reported only a few studies on the
subject, and no reliable statement on the effectiveness of
tocolytic maintenance therapy (TMT) on neonatal out-
come. Although nifedipine maintenance therapy may
increase gestational age at delivery, there has been no
improvement in neonatal or maternal outcome [18-20].
In summary, preterm delivery is an important health care
problem. Whereas it is evident that tocolysis with admin-
istration of corticosteroids for 48 hours is effective, there
is insufficient evidence for a uniform policy after these 48Page 2 of 5
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the effectiveness of maintenance therapy with nifedipine
compared to placebo therapy in women with a gestational
age below 32 weeks. Additional data will be collected for
post-hoc evaluation of the clinical relevance of cervical
length measurement and the presence of fibronectin in
cervical mucus prior to maintenance tocolytic therapy.
This study is conducted within the Dutch Obstetric Con-
sortium, a collaborative effort of obstetric clinics in The
Netherlands to perform clinical trials. All ten Dutch peri-




The aim of this study is to evaluate the effectiveness of toc-
olytic maintenance therapy on perinatal outcome after
initial standard 48-hours' tocolytic therapy in women
with threatened preterm birth between 26+0-32+2 weeks
gestational age. The outcome is measured in terms of neo-
natal mortality and composite neonatal morbidity
(chronic lung disease, severe intraventricular haemor-
rhage, periventricular leucomalacia, proven sepsis and
necrotising enterocolitis), gestational age at delivery and
costs.
Participants/eligibility criteria
Women with threatened preterm delivery with a gesta-
tional age between 26+0 and 32+2 weeks who have not
delivered after 48 hours of tocolytics and corticosteroids
are eligible for participation in the APOSTEL II-trial.
Women with both singleton and multiple gestations are
included. We chose not to include women with a gesta-
tional age between 24 and 26 weeks to prevent protocol
violation (rescue tocolysis during study medication).
Maternal exclusion criteria are signs of intrauterine infec-
tion, placenta praevia, maternal disease requiring delivery
(i.e. HELLP syndrome or preeclampsia), maternal hyper-
tension and contraindications for the use of nifedipine.
Fetal exclusion criteria are signs of fetal distress (abnormal
cardiotocogram, abnormal biophysical profile), serious
congenital defects and intrauterine death.
Procedures, recruitment, randomisation and collection of 
data
The research nurse and/or the staff of participating hospi-
tals will identify eligible women. After the patient has
given informed consent for participation in the study, she
is randomised using an internet-based procedure. Ran-
domisation is 1:1 for nifedipine or placebo.
At study entry baseline demographics, obstetric and med-
ical history are recorded. For post-hoc analysis on a subset
of women, at study entry cervical length is measured by
transvaginal ultrasound and a vaginal swab is taken for
fibronectin testing. Fibronectin will not be tested in
women with ruptured membranes, more than 3 cm dila-
tation or vaginal bleeding. Fibronectin swabs are stored
and analyzed after the patient has delivered. All data are
collected, coded and processed with adequate precautions
to ensure patient confidentiality.
Interventions
Patients are allocated to nifedipine or placebo for twelve
days. Start of study medication is 48 hours after start of the
initial tocolysis. Initial tocolysis is provided according to
local protocol, usually this will be Nifedipine or Atosiban.
Study medication consists of 20 milligrams nifedipine
every six hours, administered orally, resulting in a total
daily dose of 80 milligrams, or placebo. The medication is
phased out from day 10 (total daily dose 60 milligrams
nifedipine) till day 12 (total daily dose 20 milligrams
nifedipine) and discontinued on day 13.
After randomisation the medication package is stored by
the patient herself. The administration of the study medi-
cation is noted in a schedule that is kept both by the
patient and in her medical record. Non-compliance is
defined as a delay in administration of studymedication
of more than 6 hours.
Follow up of women and infants
All details of delivery, maternal assessments and admis-
sions during pregnancy are recorded in an electronic case
report form (CRF). Details of neonatal admissions are
also recorded. Long-term follow up of children is depend-
ing on future funding.
Outcome measures
The primary outcome measure is neonatal mortality and
a composite of neonatal morbidity. The composite mor-
bidity rate contains chronic lung disease, severe intraven-
tricular haemorrhage more than grade 2, periventricular
leucomalacia more than grade 1, proven sepsis and necr-
otising enterocolitis at six months after birth.
Secondary outcome measures are gestational age at deliv-
ery, birth weight, days on supported ventilation and addi-
tional oxygen, length of admission in neonatal intensive
care, total days in hospital until three months corrected
age and costs. Moreover, we will compare the number of
days that each neonate surpasses outside the hospital
within the first 6 months after the calculated term date.
Statistical issues
Sample size
The sample size is calculated based on an 11% reduction
in the primary outcome 'composite neonatal morbidity',Page 3 of 5
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0.05 and a power of 0.80 we have to randomise 406
patients (203 in each arm).
Data analysis
Data will initially be analysed according to the intention-
to-treat method. First, the nifedipine and placebo groups
will be compared. Relative risks and 95% confidence
intervals will be calculated for the relevant outcome meas-
ures.
Planned subgroup analysis will be performed to assess the
consistency of a treatment effect among various patient
characteristics i.e. cervical fibronectin status, presence of
ruptured membranes, multiple pregnancy as well as cervi-
cal length at study entry. We will test for interaction
between these characteristics and treatment effect.
Interim analysis
An interim analysis will be performed after the follow up
data of 100 and 200 women have been obtained. The
analyses will be done by an independent Data and Safety
Monitoring Committee (DSMC) that is not aware of treat-
ment allocation when they judge the data on effective-
ness. In case of patients reporting severe side-effects, the
DSMC can order to disclose the label of these patients.
Economic evaluation
General considerations
The aim of the economic evaluation is to compare the
optimality, in terms of costs and health effects, of mainte-
nance tocolysis with nifedipine versus placebo. As the
clinical study is based on a superiority design (it is
hypothesized that nifedipine decreases preterm birth), the
proper economic evaluation design is a cost-effectiveness
analysis (CEA): the optimal strategy will probably be
dominant, i.e. better health outcomes and lower costs.
The economic evaluation will be performed from a soci-
etal perspective.
Cost analysis
The process of care is divided into three cost stages (ante-
natal stage, delivery/childbirth, postnatal stage) and three
cost categories (direct medical costs, direct non-medical
costs and indirect costs). For each stage and each cost cat-
egory, costs are measured as the volumes of resources used
multiplied by appropriate valuations (cost-per-unit esti-
mates, fees, national reference prices).
Volumes of health care resource use are measured pro-
spectively alongside the clinical study in all participating
centres as part of the CRF.
Valuations of direct medical resources (unit costs) are esti-
mated comprising "true economic" costs, i.e. including
shares of fixed costs and hospital overheads. An analysis
based on reimbursement fees is added. Direct medical
resources used outside the hospital and direct non-medi-
cal volumes are valued using national reference prices.
Indirect costs are quantified but remain unvalued. Study-
specific costs are excluded from analysis.
Ethical consideration
This study has been approved by the ethics committee of
the Academic Medical Centre Amsterdam (Ref. no. MEC
07/286) and by the boards of management of all partici-
pating hospitals. The trial is registered in the Dutch Trial
Register, NTR 1336, http://www.trialregister.nl, date of
registration: June 3rd 2008.
Discussion
Preterm birth is responsible for approximately 75% of all
neonatal deaths and 50% of childhood neurological mor-
bidities [2]. It is also associated with high immediate and
long-term costs after discharge from the hospital [3].
To date, it is not clear whether prolonged treatment with
nifedipine is effective in reducing adverse perinatal out-
come [12,13]. On the one hand, tocolytic maintenance
therapy with calcium channel blockers may be beneficial
due to its positive effect on gestational age. On the other
hand, use of tocolytics is associated with rare but severe
side effects on mother and child [14,15]. Moreover, pro-
longation of pregnancy may also increase the chance for
some perinatal complications such as infection.
As far as we know, there are no similar ongoing studies
that will report on the subject. Neither the ISRTCN index
of trials (UK), nor IMPACT/PSANZ Perinatal Trials Regis-
try (Australian) or NIH Clinical Trial database (USA)
report any trials regarding maintenance tocolysis. There is
one ongoing study (NIFTY study) registered that com-
pares oral nifedipine with placebo, in women with single-
ton pregnancies between 24 and 34 weeks, with intact
membranes and a positive fibronectin test, in whom a full
course of corticosteroids has been completed. Primary
outcome is prolongation of pregnancy for at least seven
days. Secondary outcomes are duration and number of
NICU admissions, and maternal and neonatal hospital
costs. In this study, the sample size needed to detect a dif-
ference in neonatal morbidity or mortality between the
groups was not calculated.
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